Artavazd Arumov

Artavazd Arumov, PhD joined the Qiming US team in May 2021 and is based in the Cambridge, MA office.
Prior to joining Qiming US, Artavazd held numerous roles across the life sciences.
He led business development and therapeutic strategy for early-stage biotech Redesign Science.
Prior to Redesign Science, he completed doctorate training at the University of Miami’s Miller School of Medicine.
He also spent time in clinical research at Memorial Sloan Kettering Cancer Center, where he was responsible for the end-to-end management and operations of a portfolio of breast cancer sponsored and investigator initiated phase I/II clinical trials.
Artavazd completed his PhD in Cancer Biology at the University of Miami Miller School of Medicine’s Sylvester Comprehensive Cancer Center.
His research focused on the development and advancement of novel precision therapeutics for use in lymphoma and the study of fundamental drug resistance mechanisms.
He currently serves as an entrepreneur in residence for U Innovation’s Coulter Center for Translational Research.
He also holds a B.S.
in Biology from Brooklyn’s St. Francis College.